Carregant...
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
In the latest years, some drugs have been approved by European Medicines Agency (EMA) and/or the US Food and Drug Administration (FDA) for the treatment of patients with advanced non-small cell lung cancer (NSCLC), particularly for the treatment of those who have no targeted gene mutations or who ha...
Guardat en:
| Publicat a: | Cancer Manag Res |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6699593/ https://ncbi.nlm.nih.gov/pubmed/31616186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S212238 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|